ID

45676

Descrição

Principal Investigator: Irv L. Weissman, MD, Stanford University Medical School, Stanford, CA, USA MeSH: Breast Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001264 CD47 is a cell surface molecule that inhibits phagocytosis of cells that express it by binding to its receptor, SIRPα, on macrophages and other immune cells. CD47 is expressed at different levels in normal cells, however, in cancer cells, CD47 transcript and protein expression is aberrantly increased. Here we sought to uncover the regulators of *CD47* transcription, including active enhancers that increase its aberrant expression in cancer cells, in order to reveal mechanisms by which different neoplastic cells generate this dominant 'don't eat me' signal. Enhancers are genomic regions, often referred to as "switches", that can turn on or off the transcription of target genes. Recently the discovery of super-enhancers (SEs) has given more insight into the regulatory architecture of key genes that are highly expressed in a specific cell type, during a particular developmental stage or in disease. By analyzing the *CD47* regulatory genomic landscape, we discovered: i) A distinct super-enhancer (SE) is associated with *CD47* upregulation in breast cancer cells ii) Disruption of *CD47* SEs by using the BRD4 inhibitor JQ1 robustly reduces *CD47* gene expression; and iii) The TNF-NFKB1 signaling pathway is directly involved in the regulation of CD47 by interacting with a distal downstream constituent enhancer located within a *CD47*-associated SE specific to breast cancer. Our results describe a novel mechanism that cancer cells have evolved to drive CD47 overexpression to escape immune surveillance.

Link

dbGaP study = phs001264

Palavras-chave

Versões (1)

1. 15/04/2023 15/04/2023 - Simon Heim

Titular dos direitos

Irv L. Weissman, MD, Stanford University Medical School, Stanford, CA, USA

Transferido a

15 de abril de 2023

DOI

Para um pedido faça login.

Licença